Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Official title: A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-10-24
Completion Date
2026-10
Last Updated
2024-12-16
Healthy Volunteers
No
Conditions
Interventions
ZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Sintilimab
200 mg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Locations (1)
West China Hospital of Sichuan University
Chengdu, Sichuan, China